This past year, oncologists across the United States faced an agonizing choice: Which cancer patients would receive their full, life-saving chemotherapy regimen and which would face delays or substandard alternatives? Widespread shortages of essential drugs like cisplatin and carboplatin—workhorse medicines that form the backbone of countless cancer treatments—left doctors scrambling and put hundreds of thousands of American patients’ lives at risk.
Read Full Article »
